{
    "id": 18926,
    "fullName": "FLT3 N676S",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 N676S lies within the protein kinase domain of the Flt3 protein (UniProt.org). N676S has been demonstrated to occur as a secondary resistance mutation in the context of FLT3 internal tandem duplication (FLT3-ITD) mutations (PMID: 25847190, PMID: 15374944, PMID: 31790499), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                },
                {
                    "id": 18200,
                    "pubMedId": 31790499,
                    "title": "Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31790499"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3767,
                    "pubMedId": 15374944,
                    "title": "Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15374944"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "N676S",
    "createDate": "02/29/2016",
    "updateDate": "03/16/2020",
    "referenceTranscriptCoordinates": {
        "id": 144544,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28028204T>C",
        "cDna": "c.2027A>G",
        "protein": "p.N676S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 N676S were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19313,
                "profileName": "FLT3 exon 14 ins FLT3 N676S"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N676S mutation were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19314,
                "profileName": "FLT3 exon 14 ins FLT3 N676S FLT3 F691L"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19312,
            "profileName": "FLT3 N676S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19313,
            "profileName": "FLT3 exon 14 ins FLT3 N676S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19314,
            "profileName": "FLT3 exon 14 ins FLT3 N676S FLT3 F691L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144544,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28028204T>C",
            "cDna": "c.2027A>G",
            "protein": "p.N676S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}